Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ivermectin reduces in vivo coronavirus infection in a mouse experimental model
Ana Paula Arévalo, Romina Pagotto, Jorge L. Pórfido, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Pierre Kory, G. Umberto Meduri, Joseph Varón, et al.
American Journal of Therapeutics (2021) Vol. 28, Iss. 3, pp. e299-e318
Open Access | Times Cited: 160
Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin
Guilherme Dias de Melo, Françoise Lazarini, Florence Larrous, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 8
Open Access | Times Cited: 48
RETRACTED: Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Ali Samaha, Hussein Mouawia, Mirna Fawaz, et al.
Viruses (2021) Vol. 13, Iss. 6, pp. 989-989
Open Access | Times Cited: 37
A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody
David Scheim
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2558-2558
Open Access | Times Cited: 26
Ivermectin for treatment of COVID-19: A systematic review and meta-analysis
Zhilong Song, Senyuan Shi, Yongli Zhang
Heliyon (2024) Vol. 10, Iss. 6, pp. e27647-e27647
Open Access | Times Cited: 4
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
Xirui Zhang, Hao Yuan, Zipeng Yang, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2145-2145
Open Access | Times Cited: 20
In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice
Narayanappa Amruta, Elizabeth B. Engler-Chiurazzi, Isabel C. Murray-Brown, et al.
Life Sciences (2021) Vol. 284, pp. 119881-119881
Open Access | Times Cited: 25
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
Alessandro D. Santin, David Scheim, Peter A. McCullough, et al.
New Microbes and New Infections (2021) Vol. 43, pp. 100924-100924
Open Access | Times Cited: 25
From hydroxychloroquine to ivermectin: how unproven “cures” can go viral
Fabio Silvio Taccone, Maya Hites, Nicolás Dauby
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 4, pp. 472-474
Open Access | Times Cited: 16
Inhibition of Importin-α–Mediated Nuclear Localization of Dendrin Attenuates Podocyte Loss and Glomerulosclerosis
Maulana A. Empitu, Mitsuhiro Kikyo, Naritoshi Shirata, et al.
Journal of the American Society of Nephrology (2023) Vol. 34, Iss. 7, pp. 1222-1239
Closed Access | Times Cited: 7
Ivermectin antiviral activity against Varicellovirus bovinealpha 1: assessment of intracellular drug accumulation in virus-infected cells
Sandra Pérez, María Victoria Miró, Andrea Verna, et al.
Archives of Microbiology (2024) Vol. 206, Iss. 2
Closed Access | Times Cited: 2
Pin-Pointing the Key Hubs in the IFN-γ Pathway Responding to SARS-CoV-2 Infection
Ayelén Toro, Sofía Lage-Vickers, Juan Bizzotto, et al.
Viruses (2022) Vol. 14, Iss. 10, pp. 2180-2180
Open Access | Times Cited: 11
The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection
Gen Li, David M. P. De Oliveira, Mark J. Walker
Journal of Inorganic Biochemistry (2021) Vol. 227, pp. 111661-111661
Closed Access | Times Cited: 15
Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants
Océane Delandre, Mathieu Gendrot, Priscilla Jardot, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 4, pp. 445-445
Open Access | Times Cited: 10
Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours
Jaqueline C. Stone, Pisirai Ndarukwa, David Scheim, et al.
Biologics (2022) Vol. 2, Iss. 3, pp. 196-210
Open Access | Times Cited: 10
Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model
Takayuki Uematsu, Tomomi Takano, Hidehito Matsui, et al.
The Journal of Antibiotics (2023) Vol. 76, Iss. 8, pp. 481-488
Open Access | Times Cited: 5
Ivermectin ameliorates acute myocarditis via the inhibition of importin-mediated nuclear translocation of NF-κB/p65
Xu Gao, Yunling Xuan, Zhou Zhou, et al.
International Immunopharmacology (2024) Vol. 133, pp. 112073-112073
Closed Access | Times Cited: 1
COVID-19 and Ivermectin: Potential threats associated with human use
Tean Zaheer, Kaushik Pal, Rao Zahid Abbas, et al.
Journal of Molecular Structure (2021) Vol. 1243, pp. 130808-130808
Open Access | Times Cited: 12
Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection
Antonio Francés‐Monerris, Cristina García‐Iriepa, Isabel Iriepa, et al.
Physical Chemistry Chemical Physics (2021) Vol. 23, Iss. 40, pp. 22957-22971
Closed Access | Times Cited: 12
A comprehensive review of adverse events to drugs used in COVID‐19 patients: Recent clinical evidence
Renato Ferreira‐da‐Silva, Inês Ribeiro‐Vaz, Manuela Morato, et al.
European Journal of Clinical Investigation (2022) Vol. 52, Iss. 7
Open Access | Times Cited: 8
In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease
Yuri Alves de Oliveira Só, Katyanna Sales Bezerra, Ricardo Gargano, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 755-755
Open Access | Times Cited: 1
Blood matters: the hematological signatures of Coronavirus infection
Ayelén Toro, Ana Paula Arévalo, Marianoel Pereira‐Gomez, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 11
Open Access | Times Cited: 1
Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model
Caroline S. Foo, Rana Abdelnabi, Laura Vangeel, et al.
Microorganisms (2022) Vol. 10, Iss. 3, pp. 633-633
Open Access | Times Cited: 7
Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
Frauke Assmus, Jean‐Sélim Driouich, Rana Abdelnabi, et al.
Microorganisms (2022) Vol. 10, Iss. 8, pp. 1639-1639
Open Access | Times Cited: 6
Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection
Zsuzsanna Ragó, Barbara Tóth, Ágnes Szalenkó-Tőkés, et al.
GeroScience (2023) Vol. 45, Iss. 4, pp. 2179-2193
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top